Stay updated with breaking news from Esmo 2023. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Updated data from several clinical trials in both endometrial and cervical cancer could signal the emergence of multiple effective treatment options coming down the pike.
The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.
Expert gynecologic oncologists discuss recent progress in treating advanced endometrial and cervical cancers, including epidemiology, risk factors, evaluation, staging, and molecular testing.
Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.
Expert oncologist Aditya Bardia, MD, reflects on data from the TROPION-Breast01 trial of dato-DXd versus chemotherapy in metastatic HR+/HER2– breast cancer following ESMO 2023.